Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study

Cancer Treatment and Research Communications 2026 Open access

Read full text
Authors: Yoshihito Kogure, Hiroya Hashimoto, Satoshi Ikeda, Toshiyuki Harada, Aoi Hino, Satoru Miura, Yasuhiro Goto, Keiichi Fujiwara, Nobuyuki Katakami, Kaoru Kubota, Naohiko Murata, Masahide Mori
+5 more Takashi Abe, Akiko M. Saito, Nobuyuki Yamamoto, Hideo Saka, Masashi Kondo
DOI: 10.1016/j.ctarc.2026.101094
Cited by: 0
References: 9

Abstract

• CJLSG1901 phase 2 studied efficacy and safety of pembrolizumab plus pemetrexed • Twenty-one patients had a PD-L1 expression of

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
Cancer Treatment and Research Communications
Volume
46
Pages
101094–101094
Publication date
1 January 2026
Language
EN